| Summary: | Turner syndrome (TS) is characterized by the absence of all or part of a normal second sex chromosome in females. Around 50% of patients with TS have sex chromosome abnormalities, while the remaining half have one sex chromosome. Mutations of chromosomes in patients with TS lead to a range of clinical features including, but not limited to, short stature. Adult height of untreated women with TS is approximately 20 cm shorter than that of adult women in the general population, with the average height being around 143 cm. Recombinant human growth hormone (rhGH), also called somatropin, is used to accelerate short-term growth in girls with TS. Genotropin is one of several somatropin products available in Canada and is indicated for the treatment of short stature associated with TS in patients whose epiphyses are not closed at a dose of 0.33 mg/kg per week, divided into six to seven doses. The objective of this report was to conduct a systematic review of the benefits and harms of Genotropin compared with other available somatropin products for the treatment of short stature associated with TS.
|
|---|